全球多肽核药研究进展与我国的机遇

Global progress in peptide radiopharmaceutical research and China's opportunities

核药是核医学的灵魂,是分子影像和精准医学的重要基石之一。核药为重大疾病的早期诊断和治疗提供了物质基础。近年来,美国食品药品监督管理局(FDA)批准了多个多肽核药上市,开启了全球多肽核药研究的热潮,核医学正式迈入了精准诊疗一体化时代。围绕核医疗领域的新一轮科技竞争正在全球蔓延。抓住机遇,乘势而为,提高核药自主创新能力,确保在未来全球核科技竞争中掌握主动权,是我国核药领域科学家肩负的历史使命。本文首先概述了全球多肽核药的研发和转化方面取得的瞩目成果,分析了多肽核药的显著优势,总结了当前全球多肽核药研发的热门靶点及药物研发进展。其次,从学科交叉和源头创新的角度出发,提出了我国在多肽核药领域走内涵式发展道路,实现科技自立自强存在的六大机遇。最后,对多肽核药的未来发展进行了展望。

Radiopharmaceutical is an essential component of nuclear medicine and molecular imaging,as well as a key component of precision medicine.The United States Food and Drug Administration(FDA)has recently approved the marketing of several peptide-based radiopharmaceuticals,sparking a global trend of research in this area and propelling nuclear medicine into the precision theranostic era.This has created a new wave of technological competition in the field of nuclear medicine.It is the responsibility of Chinese scientists in the radiopharmaceutical field to capitalize on this opportunity,leverage the momentum,and strengthen their independent innovation capability in order to stay ahead in the future global nuclear science and technology competition.This review provides an overview of the remarkable progress made in the research,development,and translation of global peptide-based radiopharmaceuticals.It examines the advantages of peptide-based radiopharmaceuticals and outlines the current hot targets and progress in drug development in this field.Additionally,it proposes six opportunities for China to overtake others in the field of peptide-based radiopharmaceuticals and achieve technological self-reliance,based on interdisciplinary collaboration and independent innovation.Lastly,the future prospect of peptide-based radiopharmaceuticals is discussed.